Long-Term Tadalafil Use Linked to Increased Glaucoma Risk in Men Taking Medication for Prostate Symptoms

Men who take the popular erectile dysfunction and prostate medication tadalafil—widely known by its brand name Cialis—over extended periods may face a moderately elevated risk of developing glaucoma, according to a large-scale comparative study published in the British Journal of Ophthalmology. The research, which analyzed health data from nearly 74,000 male patients, highlights a potential link between chronic use of phosphodiesterase type 5 inhibitors (PDE5i) and adverse ocular health outcomes. While the findings do not establish a definitive cause-and-effect relationship, authors of the study recommend heightened vigilance, urging routine eye examinations for patients undergoing long-term therapy, particularly those with pre-existing risk factors for vision loss.

The implications of this study extend across multiple medical disciplines, intersecting urology, cardiology, and ophthalmology. Tadalafil and other medications in the PDE5i class, such as sildenafil (marketed as Viagra) and vardenafil (Levitra), have transformed the treatment landscape for erectile dysfunction since their introduction in the late 1990s. Over the past two decades, however, clinicians have increasingly prescribed tadalafil on a daily, low-dose basis to alleviate lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland that affects a significant proportion of aging men.

Because daily dosing for BPH involves uninterrupted, long-term exposure to the drug compared to the episodic use typically associated with treating erectile dysfunction, researchers sought to determine whether chronic exposure alters ocular physiology in ways that could elevate the risk of optic nerve damage and increased intraocular pressure.

Background Context: The Intersection of PDE5 Inhibitors and Ocular Physiology

To understand the scope of the recent study, it is necessary to examine how PDE5 inhibitors function within the human body. These medications work by blocking the enzyme phosphodiesterase type 5, which regulates blood flow and smooth muscle tone. By inhibiting this enzyme, the drugs promote the relaxation of smooth muscles and increase blood circulation to targeted tissues.

While this mechanism is highly effective for treating erectile dysfunction and easing urinary obstruction caused by an enlarged prostate, the enzyme PDE5 is also present in other tissues throughout the body, including the eye. Previous scientific investigations have established biological plausibility for ocular side effects. Researchers have previously connected PDE5i medications to various visual disturbances, ranging from temporary color vision changes to more serious conditions affecting the macula—the central part of the retina responsible for sharp, detailed vision—and ischemic optic neuropathy, a condition characterized by restricted blood flow to the optic nerve.

Despite these established concerns, data regarding the specific association between tadalafil and glaucoma—a progressive eye disease characterized by damage to the optic nerve, often linked to elevated intraocular pressure—has remained inconclusive. Prior studies offered conflicting results, with some suggesting a temporary drop in ocular perfusion pressure and others finding no statistically significant link. Furthermore, virtually no large-scale investigations had focused specifically on patients utilizing the drug continuously for lower urinary tract symptoms over multi-year periods.

Methodology and Study Design: Analyzing Nearly 74,000 Patient Records

To address this critical gap in medical literature, an international research team designed a retrospective comparative cohort study utilizing anonymized real-world health data from the TriNetX Analytics Network, a vast global collaborative database of electronic health records.

The study population comprised 73,854 male patients aged 40 and older. The cohort was divided equally into two distinct groups to compare health outcomes over a five-year observation window spanning from January 2012 to December 2022. The treatment group consisted of 36,927 men who had been prescribed tadalafil or another PDE5 inhibitor for up to five years to manage urinary tract symptoms related to benign prostatic hyperplasia. The control group consisted of an identical number of matched male patients who had not received prescriptions for these medications.

To ensure the integrity of the comparison and eliminate potential confounding variables, researchers meticulously matched the participants across a broad spectrum of demographic and clinical factors. The matching criteria accounted for age, racial background, smoking status, alcohol-related disorders, concurrent prescription medications, and a comprehensive list of underlying health conditions. These comorbidities included cardiovascular disease, diabetes mellitus, malignant neoplasms, hyperlipidemia (high cholesterol), chronic kidney disease, obesity, and chronic obstructive pulmonary disease (COPD).

By controlling for these variables, the research team aimed to isolate the association between long-term PDE5i exposure and the subsequent diagnosis of glaucoma, ocular hypertension, or the initiation of glaucoma-specific medical therapies.

Key Findings: A 22% Increase in Glaucoma Risk

Upon analyzing the five-year follow-up data, the researchers uncovered statistically significant differences between the two cohorts. Men who had been prescribed tadalafil exhibited a 22% higher overall likelihood of developing glaucoma compared to their matched peers in the control group who had not taken the medication.

The study also tracked several related ocular conditions and clinical endpoints, revealing consistent trends across multiple diagnostic categories:

• Ocular hypertension (elevated pressure within the eye) was found to be 32% more common among patients prescribed tadalafil.
• Primary open-angle glaucoma, which represents the most prevalent form of the disease, showed a 33% increase in risk.
• The initiation of formal treatment regimens for glaucoma occurred 33% more frequently in the tadalafil cohort.

To test the robustness of these findings, the research team performed secondary analyses. The positive associations remained consistent even when examining subgroups of patients who developed glaucoma relatively soon after initiating tadalafil treatment—specifically within one, three, or six months of their initial prescription. Furthermore, the elevated risk pattern persisted across specific demographic and clinical segments, including patients aged 50 and older, white participants, and individuals presenting with multiple underlying medical comorbidities.

Limitations of the Observational Study

Despite the strength of the statistical analysis and the large sample size, the study authors emphasize several important limitations that preclude drawing a definitive causal link between tadalafil and glaucoma.

Because the research was observational in nature—relying on electronic health records rather than a randomized controlled trial—it can identify correlations and associations, but it cannot definitively prove that tadalafil directly causes glaucoma. Observational studies are inherently subject to unmeasured confounding factors. For instance, the researchers could not independently verify patient adherence or track dynamic changes in actual medication usage over the five-year period. Additionally, the database lacked granular tracking for newly emerging lifestyle factors or sub-clinical changes in underlying health conditions that were not formally documented in clinical notes.

Another notable limitation involves the demographic composition of the study population. The vast majority of participants included in the analysis were of white racial background. Consequently, the researchers caution that the findings may not be directly generalizable to men from other ethnic or racial groups, whose baseline physiological responses to PDE5 inhibitors and genetic susceptibility to glaucoma may differ.

The authors summarize these constraints by noting that while the data points toward a clear statistical association, further mechanistic investigations are required to understand how chronic PDE5 inhibition interacts with ocular physiology over time.

Clinical Implications: Balancing Benefits and Ocular Health

The publication of these findings has sparked discussions among urologists, primary care physicians, and ophthalmologists regarding patient management strategies. Crucially, medical professionals and the study authors themselves stress that the research does not indicate that patients should discontinue their tadalafil prescriptions. For millions of men, tadalafil provides profound improvements in quality of life by effectively managing debilitating urinary symptoms and erectile dysfunction.

Instead, the clinical community is interpreting the study as a call for proactive risk stratification and enhanced interdisciplinary communication. Patients who rely on daily tadalafil for benign prostatic hyperplasia often fall into older age brackets, a demographic already at elevated baseline risk for degenerative eye diseases.

Medical experts suggest that incorporating baseline ophthalmic evaluations before initiating long-term PDE5i therapy could represent a vital step in safeguarding patient vision. Regular follow-up eye examinations are deemed especially critical for individuals who carry known risk factors for glaucoma. These risk factors include:

• A documented family history of glaucoma
• Pre-existing ocular hypertension
• High myopia (severe short-sightedness)
• Advanced age
• Extended duration of daily PDE5i therapy

The study authors conclude their report with a clear recommendation for clinical practice: “These findings do not contraindicate tadalafil use but highlight the importance of baseline ophthalmic assessment and regular follow-up, particularly in patients with pre-existing glaucoma, ocular hypertension, a family history of glaucoma, high myopia, or those requiring long-term therapy.”

Future Directions in Ophthalmology and Urology

As the use of daily low-dose tadalafil continues to expand globally alongside aging populations, the intersection of urological therapies and long-term systemic side effects will remain an active area of clinical research. Ophthalmologists and urologists are increasingly advocating for integrated care models where patients prescribed chronic medications that affect blood flow or smooth muscle regulation are simultaneously monitored for subtle shifts in ocular health.

Future research initiatives are expected to focus on prospective clinical trials and mechanistic laboratory studies to determine whether the observed association is driven by changes in ocular perfusion pressure, direct cellular effects within the optic nerve head, or other vascular pathways. Until such data becomes available, the medical consensus remains focused on balanced patient care: maximizing the therapeutic benefits of medications like tadalafil while ensuring that routine eye health is not overlooked in the management of chronic conditions.